Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles

LONDON (Reuters) – Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan’s Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply